NOVARTIS
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
Tolerability of Indacaterol Salts (Maleate, Xinafoate and Acetate) in Comparison to Placebo in Patients With Mild to Moderate Persistent Asthma
- First Posted Date
- 2008-02-27
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Novartis
- Target Recruit Count
- 98
- Registration Number
- NCT00624702
- Locations
- 🇨🇦
Novartis Investigator Site, Montreal, Quebec, Canada
Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Interventions
- First Posted Date
- 2008-02-27
- Last Posted Date
- 2011-08-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 416
- Registration Number
- NCT00624286
- Locations
- 🇧🇪
Novartis Investigative Site, Lanaken, Belgium
🇳🇿Novartis Investigator Site, Tauranga, New Zealand
A Study of Efficacy of New Doses of Xolair to Protect From Allergen Challenge in Groups of Asthma Patients Defined by IgE Levels
- First Posted Date
- 2008-02-27
- Last Posted Date
- 2011-04-19
- Lead Sponsor
- Novartis
- Target Recruit Count
- 60
- Registration Number
- NCT00624832
- Locations
- 🇿🇦
Novartis Investigator Site, Durban, South Africa
A 24 Week, Multicenter, Open, Evaluation of the Clinical Effectiveness of the Once-daily 10 cm^2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (EXTRA)
- Conditions
- First Posted Date
- 2008-02-25
- Last Posted Date
- 2011-07-26
- Lead Sponsor
- Novartis
- Target Recruit Count
- 228
- Registration Number
- NCT00622713
- Locations
- 🇫🇷
Novartis Investigative Site, Rueil-Malmaison, France
Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD)
- Conditions
- Interventions
- First Posted Date
- 2008-02-25
- Last Posted Date
- 2011-11-28
- Lead Sponsor
- Novartis
- Target Recruit Count
- 583
- Registration Number
- NCT00623103
- Locations
- 🇺🇸
Collier Neurologic Specialists, Naples, Florida, United States
🇺🇸Neurological Associates, Meridian, Idaho, United States
🇺🇸Progressive Clinical Research, Bountiful, Utah, United States
Safety and Tolerability of Single and Multiple Doses of VAK694 in Healthy and Atopic Subjects
- First Posted Date
- 2008-02-21
- Last Posted Date
- 2010-09-27
- Lead Sponsor
- Novartis
- Target Recruit Count
- 46
- Registration Number
- NCT00620230
- Locations
- 🇺🇸
Novartis Investigator Site, North Miami Beach, Florida, United States
The Effect of Indacaterol on Exercise Endurance in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
- Conditions
- Interventions
- First Posted Date
- 2008-02-21
- Last Posted Date
- 2011-08-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 90
- Registration Number
- NCT00620022
- Locations
- 🇪🇸
Novartis Investigative Site, Madrid, Spain
🇪🇸Novartis Investigator Site, Zaragoza, Spain
🇪🇸Novartis Investigative site, Seville, Spain
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Patients With Rheumatoid Arthritis With Ongoing Treatment With Methotrexate
- First Posted Date
- 2008-02-21
- Last Posted Date
- 2008-02-21
- Lead Sponsor
- Novartis
- Target Recruit Count
- 53
- Registration Number
- NCT00619905
- Locations
- 🇨🇭
Novartis Investigator Site, Geneva, Switzerland
Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency
- First Posted Date
- 2008-02-15
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 148
- Registration Number
- NCT00616811
- Locations
- 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
🇺🇸University of Cincinnati, Cincinnati, Ohio, United States
🇺🇸Anasazi Internal Medicine, Phoenix, Arizona, United States
Study of Indacaterol Dosed in the Evening in Patients With Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Interventions
- First Posted Date
- 2008-02-14
- Last Posted Date
- 2011-08-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 96
- Registration Number
- NCT00615030
- Locations
- 🇪🇸
Novartis Investigative Site, Barcelona, Spain